MedTrace Logo

Pharmacokinetic Study in Healthy Volunteers

NCT02554734 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2016-01-14

No results posted yet for this study

Summary

Phase I open, randomized cross-over pharmacokinetic study.

Conditions

Interventions

DRUG

levodopa, carbidopa, ODM-104

DRUG

levodopa, carbidopa, entacapone

Sponsors & Collaborators

  • Orion Corporation, Orion Pharma

    lead INDUSTRY

Principal Investigators

  • Mika Scheinin, MD · Clinical Research Services Turku CRST

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02554734 on ClinicalTrials.gov